Look in the MIRROR From the College | October 26, 2023 The MIRROR trial “provides good evidence for concomitant therapy with methotrexate and pegloticase to reduce the occurrence of immunogenicity and prolong the period before drug withdrawal is necessitated,” says Dr. Lisa Stamp, a New Zealand rheumatologist who has extensively researched the pathophysiology and management of gout. She discussed the MIRROR trial and other cutting-edge research in an article following ACR Convergence 2022. The MIRROR trial demonstrated that using 15 mg of oral methotrexate weekly with pegloticase results in: A. A sustained urate-lowering response rate in the methotrexate group at month 6 vs. the placebo co-therapy group B. A lower rate of infusion reactions in the methotrexate group C. No difference in urate-lowering response between groups, but fewer infusion reactions in the methotrexate group D. A and B None Time's up
